ArticleMediators of inflammation2026
Geniposide Alleviates Inflammatory Bowel Disease by Regulating Intestinal Flora and Arginine Metabolism and Inhibiting the NF-κB Pathway Through Targeting Anxa5.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundInflammatory bowel disease (IBD), including Crohn's and ulcerative colitis (UC), is a chronic gut inflammation thought to be caused by gut microbial causes and immune system dysfunction. Geniposide (GEN) is a natural compound shown to prevent IBD; however, its mechanism of modifying the gut microbiome, regulating arginine metabolism, and inhibiting the nuclear factor kappa B (NF-κB) pathway by targeting Annexin A5 (Anxa5) remains unexplored.
methodsThis study examined the regulation of intestinal immunity, gut microbiota, metabolites, and associated activities and pathways, as well as the NF-κB pathway by GEN in a BALB/c mouse model of IBD. The mouse macrophage cell line (RAW264.7) was further utilized to investigate the role of GEN on the macrophage-arginine metabolism and the Anxa5 axis. qRT-PCR, Western blotting, hematoxylin and eosin (H&E), immunohistochemistry (IHC), immunofluorescence (IF), fecal 16S rDNA sequencing, and UHPLC/Q-TOF-MS were used to evaluate the treatment effect of GEN. Drug target sequencing and small interfering RNA (siRNA) were used to establish the target molecule of GEN.
resultsGEN therapy improved colon and spleen tissues, decreased the disease activity index, helped mice maintain their weight, elevated anti-inflammatory cytokines and tight junction proteins, and decreased proinflammatory cytokines. GEN modulated the quantity of dysfunctional metabolites and enhanced the structure and diversity of the gut microbial community. GEN restored the underpopulated genera Enterorhabdus, Rikenella, Anaerotruncus, and Alistipes, regulating arginine metabolism mediated by G-guanidinobutyrate in RAW264.7 cells and the gut mucosa to protect the colon. GEN targeted Anxa5, enhancing its expression in both animal models and RAW264.7 cells. Following Anxa5 knockdown, cyclooxygenase-2 (COX-2) expression increased, along with the activation of NF-κB pathway-related proteins in RAW264.7 cells. GEN reduced the levels of NF-κB pathway-related proteins in both RAW264.7 cells and animal models.
conclusionGEN mitigated colitis by regulating the intestinal microbiota and arginine metabolism and inhibiting the NF-κB pathway via targeting Anxa5.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.